mmHg Inc. is pleased to announce that it has secured institutional investment from the Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest.
The funding will be used to refine mmHg’s industry leading cardiometabolic platform-as-a-service and expand global operations.
mmHg CEO Raj Padwal stated, ‘We are honoured to be selected by CABHI as a recipient of this investment within the MC2 Capital cohort. We are looking forward to working with CABHI to bring mmHg innovations to the global market.’
A solution accelerator for the aging and brain health sector, CABHI provides funding and support to innovators for the development, testing, and dissemination of new ideas and technologies that address unmet brain health and seniors’ care needs.
As a hands-on investor, CABHI’s acceleration services include access to an innovation network of 200+ distribution channels and industry organizations, 100+ experts through a coaches community, and financial, legal, and regulatory benefits and discounts from corporate partners.
In addition, CABHI offers end-user testing, customer discovery, and subsidies for internship/co-op student placements to MC2 companies.